Michele M. Oshman is Chief Patient Advocate and Head of the Patient Advocacy Center of Excellence at the Biotechnology Innovation Organization, the world’s largest trade association representing biotechnology companies in health, agriculture, and the environment. She leads BIO’s patient advocacy team, overseeing engagement with patient groups and key stakeholders, supporting member organizations, and ensuring patient perspectives are reflected in BIO’s policy work. Ms. Oshman joined BIO in 2020 after 18 years at Eli Lilly and Company, where she led federal alliance development outreach and held various roles in clinical development, advocacy, and corporate leadership. She earned a Six Sigma Black Belt and led several enterprise-wide transformation initiatives. She serves on the Board of Directors for the National Health Council, a coalition of over 160 health-related organizations advancing patient-centered health policy. She is also serving her second term on the Board of the American Brain Coalition, a nonprofit promoting brain health through professional and academic collaboration. In 2023, Ms. Oshman was elected to Health On Wednesday, an exclusive group of 45 senior women leaders in health policy. She also serves on the Committee on Nominations and Leadership Development for the American Association for the Advancement of Science (AAAS)An active member of the Japan America Society of Washington, D.C. Ms. Oshman holds dual degrees in Political Science and Communications from American University. She lives in Washington, DC, with her husband of over 25 years, their two children.